A fixed-dose combination syrup used for the symptomatic management of productive cough and bronchospasm associated with acute and chronic respiratory conditions. It combines a mucolytic (Ambroxol), a selective beta-2 agonist bronchodilator (Levosalbutamol), and an expectorant (Guaifenesin) to provide comprehensive relief by loosening thick mucus, facilitating its expulsion, and opening the airways.
Adult: 10 ml (2 teaspoonfuls) two to three times daily. Maximum: 30 ml per day.
Note: Take orally after meals with a full glass of water to minimize gastric upset and aid expectoration. Use the measuring cup/spoon provided. Shake the bottle well before use.
The combination works synergistically: Ambroxol reduces mucus viscosity by breaking down acid mucopolysaccharide fibers and stimulates surfactant production. Guaifenesin increases respiratory tract fluid secretion, reducing mucus adhesiveness and surface tension. Levosalbutamol relaxes bronchial smooth muscle via beta-2 adrenergic receptor stimulation, relieving bronchospasm and improving mucociliary clearance.
Pregnancy: Category C (US FDA). Ambroxol and Guaifenesin: Data limited. Levosalbutamol: Should be used only if potential benefit justifies potential risk to fetus. Use in first trimester not recommended unless absolutely necessary. Consult physician.
Driving: Use caution. May cause dizziness, nervousness, or tremor, impairing ability to drive or operate machinery.
| Beta-blockers (e.g., Propranolol) | Antagonizes bronchodilator effect of Levosalbutamol; may cause severe bronchospasm in asthmatics. | Major |
| Diuretics (e.g., Furosemide, Hydrochlorothiazide) | Concurrent use with Levosalbutamol may potentiate hypokalemia. | Major |
| Digoxin | Hypokalemia from Levosalbutamol may increase risk of digoxin toxicity. | Moderate |
| Monoamine Oxidase Inhibitors (MAOIs) & Tricyclic Antidepressants (TCAs) | May potentiate the cardiovascular effects of Levosalbutamol. | Moderate |
| Other Sympathomimetics (e.g., Decongestants) | Additive cardiovascular effects (tachycardia, hypertension). | Moderate |
| Xanthine derivatives (Theophylline) | Increased risk of CNS stimulation and cardiac effects. | Moderate |
| Anticholinergics (e.g., Ipratropium) | Potential additive bronchodilatory effect; also increased risk of urinary retention. | Moderate |
| CNS Depressants (Alcohol, Benzodiazepines) | Guaifenesin in high doses may have mild sedative effect; additive sedation possible. | Minor |
Same composition (Ambroxol (30mg/5ml) + Levosalbutamol (1mg/5ml) + Guaifenesin (50mg/5ml)), different brands: